188 related articles for article (PubMed ID: 38631708)
21. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
[TBL] [Abstract][Full Text] [Related]
22. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
Lim O; Lee Y; Chung H; Her JH; Kang SM; Jung MY; Min B; Shin H; Kim TM; Heo DS; Hwang YK; Shin EC
PLoS One; 2013; 8(1):e53611. PubMed ID: 23326467
[TBL] [Abstract][Full Text] [Related]
23. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
24. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
25. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.
Peng BG; Liang LJ; He Q; Huang JF; Lu MD
World J Gastroenterol; 2004 Jul; 10(14):2119-23. PubMed ID: 15237448
[TBL] [Abstract][Full Text] [Related]
26. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
27. Cytokines impact natural killer cell phenotype and functionality against glioblastoma
Sivonen M; Sirviö KA; Wojciechowski S; Kailaanmäki A; Kaipainen S; Bailey A; Villalba M; Kekarainen T
Front Immunol; 2023; 14():1227064. PubMed ID: 37841273
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.
Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D
J Immunother; 2012 Sep; 35(7):579-86. PubMed ID: 22892454
[TBL] [Abstract][Full Text] [Related]
29. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
[TBL] [Abstract][Full Text] [Related]
30. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells.
Lee DA
Immunol Rev; 2019 Jul; 290(1):85-99. PubMed ID: 31355489
[TBL] [Abstract][Full Text] [Related]
31. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
[TBL] [Abstract][Full Text] [Related]
32. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.
Vasu S; Berg M; Davidson-Moncada J; Tian X; Cullis H; Childs RW
Cytotherapy; 2015 Nov; 17(11):1582-93. PubMed ID: 26432560
[TBL] [Abstract][Full Text] [Related]
33. Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Yamada S; Nakagawa I; Park YS; Nakase H; Tsujimura T
Regen Ther; 2022 Dec; 21():185-191. PubMed ID: 35919498
[TBL] [Abstract][Full Text] [Related]
34. Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy.
Al-Kadhimi Z; Callahan M; Fehniger T; Cole KE; Vose J; Hinrichs S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109387. PubMed ID: 36461582
[TBL] [Abstract][Full Text] [Related]
35. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
[TBL] [Abstract][Full Text] [Related]
36. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
38. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.
Kisseberth WC; Lee DA
Front Vet Sci; 2021; 8():672361. PubMed ID: 34164452
[TBL] [Abstract][Full Text] [Related]
39. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice.
Xun C; Brown SA; Jennings CD; Henslee-Downey PJ; Thompson JS
Transplantation; 1993 Aug; 56(2):409-17. PubMed ID: 8356598
[TBL] [Abstract][Full Text] [Related]
40. [Selective expansion of human natural killer cells].
Peng BG; Liang LJ; He Q; Li J; Lu MD
Ai Zheng; 2005 Oct; 24(10):1287-9. PubMed ID: 16219151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
